Pfizer Inc. logo
Pfizer Inc. (PFE)
Compare

Pfizer Inc. (PFE) Earnings Per Share (EPS): 1.31

popular:market cap|pe ratio|revenue|price history|total return

Is Pfizer Inc.’s earnings per share (EPS) high or low?

Pfizer Inc.'s earnings per share (EPS) of 1.31 is 45% below its 5-year average of 2.39, near the low end of its 5-year range (0.38–5.59).

The earnings per share (EPS) for Pfizer Inc. (PFE) is 1.31 as of Tuesday, June 9, 2026. It is below its 12-month average by 5.76% (1.39).

P/E Ratio|EPS CAGR|Net Income|Earnings Yield|All Metrics

PFE Earnings Per Share (EPS) Chart

PFE Earnings Per Share (EPS)
1.36-4.23% 1Y
Zoom

PFE Average Earnings Per Share (EPS) Chart

PFE Current vs Average Earnings Per Share (EPS) Chart

PFE Earnings Per Share (EPS) Metrics

EARNINGS PER SHARE (EPS)

1.31

EARNINGS PER SHARE (EPS) AVG TTM

1.39

EARNINGS PER SHARE (EPS) AVG 3Y

2.19

EARNINGS PER SHARE (EPS) AVG 5Y

2.39

EARNINGS PER SHARE (EPS) AVG 10Y

2.28

EARNINGS PER SHARE (EPS) AVG 15Y

1.98

EARNINGS PER SHARE (EPS) AVG 20Y

1.80

CURRENT VS TTM AVG

-5.76%

CURRENT VS 3Y AVG

-40.10%

CURRENT VS 5Y AVG

-45.23%

CURRENT VS 10Y AVG

-42.47%

CURRENT VS 15Y AVG

-33.77%

CURRENT VS 20Y AVG

-27.23%

PFE Competitors' Earnings Per Share (EPS)

NAMEMARKET CAPEARNINGS PER SHARE (EPS)TTM3Y5Y
Pfizer Inc. (PFE)—1.311.392.192.39
Intuitive Surgical, Inc. (ISRG)$151.09B8.257.275.845.20
Gilead Sciences, Inc. (GILD)$155.82B7.343.613.853.41
Abbott Laboratories (ABT)$158.94B3.595.714.664.19
Danaher Corporation (DHR)$133.37B5.175.206.666.73
CVS Health Corporation (CVS)$123.84B2.272.533.714.39
Bristol-Myers Squibb Company (BMY)$115.34B3.56-0.481.470.84
Vertex Pharmaceuticals Incorporated (VRTX)$113.14B16.866.6910.109.99
Thermo Fisher Scientific Inc. (TMO)$183.61B18.1917.1716.9017.22
Amgen Inc. (AMGN)$185.96B14.3710.9711.6711.57

EPS Comparison

Trailing EPS (TTM)

$1.31

Forward EPS (Est.)

$2.83

P/E Ratio

19.6

Formula: EPS = Net Income / Weighted Average Shares Outstanding

Why EPS matters:

  • Directly impacts stock valuation through P/E ratio
  • Used to calculate dividend coverage and payout ratios
  • Enables comparison across companies of different sizes
  • Growth in EPS often correlates with stock price appreciation

Pfizer Inc. Earnings Per Share (EPS) Formula & Definition

EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Pfizer Inc. Earnings Per Share (EPS) FAQ

What is the earnings per share (EPS) for Pfizer Inc. (PFE)?
The earnings per share (EPS) for PFE stock is 1.31.
Is Pfizer Inc.'s earnings per share (EPS) high or low?
Pfizer Inc.'s earnings per share (EPS) of 1.31 is 45% below its 5-year average of 2.39, near the low end of its 5-year range (0.38–5.59).
What is the TTM average earnings per share (EPS) for Pfizer Inc. (PFE)?
The TTM average earnings per share (EPS) for PFE stock is 1.39.
What is the 3Y average earnings per share (EPS) for Pfizer Inc. (PFE)?
The 3Y average earnings per share (EPS) for PFE stock is 2.19.
What is the 5Y average earnings per share (EPS) for Pfizer Inc. (PFE)?
The 5Y average earnings per share (EPS) for PFE stock is 2.39.
What is the 10Y average earnings per share (EPS) for Pfizer Inc. (PFE)?
The 10Y average earnings per share (EPS) for PFE stock is 2.28.
What is the 15Y average earnings per share (EPS) for Pfizer Inc. (PFE)?
The 15Y average earnings per share (EPS) for PFE stock is 1.98.
What is the 20Y average earnings per share (EPS) for Pfizer Inc. (PFE)?
The 20Y average earnings per share (EPS) for PFE stock is 1.80.

Pfizer Inc. Earnings Per Share (EPS) History

DATEEARNINGS PER SHARE (EPS)
2025-12-311.36
2024-12-311.42
2023-12-310.38
2022-12-315.59
2021-12-313.95
2020-12-311.65
2019-12-312.92
2018-12-311.90
2017-12-313.57
2016-12-311.18
2015-12-311.13
2014-12-311.43
2013-12-311.71
2012-12-311.32
2011-12-311.11
2010-12-311.03
2009-12-311.23
2008-12-311.19
2007-12-311.19
2006-12-311.52
2005-12-311.03
2004-12-311.51
2003-12-310.54
2002-12-311.48
2001-12-311.25
2000-12-310.60
1999-12-310.81
1998-12-310.89
1997-12-310.58
1996-12-310.52

Related Metrics

P/E RatioEPS CAGRNet IncomeEarnings YieldAll Metrics

About Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

New York City, NY
81,000 employees
www.pfizer.com
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Albert Bourla
View full financials